We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Belviq

News List

Weight Control Drug Lorcaserin May Raise Cancer Risk drugs
January 16, 2020
The prescription weight control medicine lorcaserin (Belviq, Belviq XR) may increase the risk for cancer, according to the results of a clinical trial assessing the safety of the drug, the U.S. Food and Drug Administration says.
FDA issues alert for cancer risk from Belviq (lorcaserin) europeanpharmaceuticalreview
January 16, 2020
The US FDA has announced a warning to healthcare professionals and patients that the weight management drug Belviq may be a cause of cancer.
Study shows Eisai's obesity drug Belviq does not increase major cardiovascular events firstwordpharma
August 29, 2018
Study results presented at the European Society of Cardiology (ESC) congress showed that in a high-risk population of overweight or obese patients, Eisai's Belviq (lorcaserin) was associated with sustained weight loss without a higher rate of major cardio